A novel modelling framework to simulate the effects of HIV stigma on HIV transmission dynamics

Donal Bisanzio^{1§}, Sarah T. Roberts², Rachel D. Stelmach¹, Kendall N. McClellan³, Georgiy Bobashev², Joella Adams², Katherine Karriker-Jaffe², Stacy M. Endres-Dighe^{2,4}, Khalida Saalim¹, Natalie Blackburn², Laura Nyblade²

¹ International Development Group, RTI International, Research Triangle Park, NC, USA

² Social, Statistical, and Environmental Sciences Business Unit, RTI International, Research Triangle Park, NC, USA

³ Department of Mathematics and Statistics, Georgetown University, Washington, DC, USA

⁴ Department of Epidemiology, Ohio State University, Columbus, OH, USA

[§] Corresponding author: Donal Bisanzio

Street address: Wilmslow Road, The Pavilion, Towers Business Park, Manchester, M20 2LS United Kingdom Email: dbisanzio@rti.org

Keywords: HIV; Social Stigma; Computer Models; Agent-based Modelling; Treatment Adherence and Compliance; HIV Infections, Prevention & Control

1 ABSTRACT

2 Introduction

3 HIV remains a global public health challenge, with social determinants such as stigma influencing

4 transmission dynamics, access to testing, and treatment. HIV stigma shapes both individual behaviour and

5 community responses to HIV. However, modelling approaches have rarely represented the complex role

6 of stigma in HIV epidemics. Our study introduces an innovative modelling framework designed to

7 capture the interplay between stigma and HIV transmission dynamics.

8 Methods

9 We modelled effects of anticipated, internalised, and experienced HIV stigma on HIV testing,

10 antiretroviral treatment initiation, and treatment adherence. We built an individual-based model

11 representing the HIV epidemic (HIV-IBM) in a USA-like population of 3 million individuals that

12 accounts for community demography, behaviour, and healthcare access. Stigma parameters were based on

13 a scoping review focused on the prevalence and effects of stigma in people living with and without HIV.

14 HIV-IBM was used to assess effects of interventions targeting different types of stigma. We tested

15 reductions of stigma by 50% and 100% across the simulated population and performed a sensitivity

16 analysis to identify effects of each type of stigma on the simulated HIV epidemic.

17 **Results**

18 Without reduced stigma, the HIV-IBM had an annual incidence rate of 12.6 (95% credible interval [CI]:

19 11.4-13.5) new cases per 100,000 people. Reducing the overall level of stigma in the population by 50%

20 resulted in an annual incidence rate of 9.6 (95% CI: 8.6-10.3) per 100,000, and a 100% reduction in

stigma resulted in an annual incidence rate of just 6.8 (95% CI: 6.1-7.3) per 100,000. In addition to

22 reducing HIV incidence, reducing stigma resulted in a substantial increase of viral suppression among

23 people living with HIV (50% stigma reduction: +10.5%; 100% stigma reduction: +16.4%). Sensitivity

24 analysis showed that outcomes resulting from interventions targeting each type of stigma were highly

25 heterogeneous.

26 Conclusion

- 27 Simulation results suggest that reducing HIV stigma could have a large effect on HIV incidence and viral
- 28 suppression. Our model framework provides a dynamic approach to understanding the role of stigma in
- 29 HIV outcomes that facilitates exploration of stigma reduction strategies and offers insights to inform
- 30 evidence-based policies and interventions for reducing stigma and curtailing HIV.

31

32

33 INTRODUCTION

HIV remains a global public health challenge, with over 39 million people living with HIV (PLWH) and 34 35 about 1.3 million new cases globally in 2022, including 31,800 new cases in the United States (US).(1) 36 Both the UNAIDS Global AIDS Strategy and U.S. Ending the HIV Epidemic Initiatives have set targets of 37 95% of PLWH aware of their status, 95% linkage to care among those diagnosed with HIV, and 95% viral 38 load suppression among those linked to care by 2025.(2,3) Despite some countries' success, many more 39 are unlikely to meet these targets. In the US in 2022, 87% of PLWH were aware of their status, and 40 among those, 83% have been linked to care and 65% were virally suppressed.(4) 41 HIV stigma shapes both individual behaviour and community responses to HIV, as well as transmission dynamics and utilisation of testing and treatment. As described by Turan and colleagues (5), forms of HIV 42 43 stigma can include enacted or experienced HIV stigma, which occurs when people experience actual 44 discriminatory actions due to their HIV status; perceived HIV stigma, which describes the negative 45 attitudes a person believes other people hold about PLWH; anticipated HIV stigma, which occurs when a 46 person expects that other people will treat them badly due to their HIV status; and internalised HIV 47 stigma, which occurs when PLWH accepts that negative stereotypes about PLWH are true and applicable 48 to themself. These types of HIV stigma have been demonstrated to influence uptake and adherence to 49 highly effective interventions such as HIV testing, antiretroviral therapy (ART), and pre-exposure 50 prophylaxis (PrEP), as well as HIV-related health outcomes such as viral load suppression, although 51 results vary across study designs, measures, and populations.(6–13) 52 Mathematical models can synthesize key evidence for understanding the HIV epidemic; informing policy 53 decisions; predicting long-term health outcomes; and characterizing the interaction of biological, social, 54 and behavioural factors to reduce or exacerbate those outcomes. Despite the known influence of stigma 55 on HIV transmission and progression, HIV models have rarely included stigma.(14–19) Modellers choose 56 to exclude stigma due to perceptions that stigma is too complex, poorly understood, or difficult to

57 measure to implement in a modelling process.(14,17,18) Not accounting for stigma when estimating the

effectiveness of HIV-related interventions omits important public health considerations and prevents policymakers from fully evaluating the potential impact of stigma-reduction interventions. These interventions may have greater benefit than expected due to the cumulative effect of stigma on multiple steps of the prevention and treatment cascade. In this mathematical modelling study, we introduce an innovative framework designed to estimate the effects of anticipated, internalised, and experienced HIV stigma on HIV testing, treatment, and transmission dynamics.

64 METHODS

65 We estimated the impact of interventions targeting stigma using an individual based model (HIV-IBM) 66 representing a synthetic population of a hypothetical city of 3 million people in the US. We provide an 67 overview of the HIV-IBM here, with a more detailed description of the model provided in the Appendix. 68 The HIV-IBM simulates HIV transmission through two main HIV transmission routes: syringe sharing 69 among people who inject drugs (PWID) and sexual intercourse among serodiscordant partners. Thus, the 70 HIV-IBM includes two contact networks, with one representing the sexual network and another capturing 71 needle sharing among PWID. The HIV-IBM's sexual network simulates sexual contacts among 72 individuals above 14 years of age in the USA. This network accounts for sexual contact of men who have 73 sex with women (MSW), women who have sex with men (WSM), men who have sex with men (MSM), 74 women who have sex with women (WSW), men who have sex with both men and women (MSMSW), 75 and women who have sex with both women and men (WSWSM). This approach assumes that transgender 76 individuals identify as either a man or a woman and notably omits behaviours of individuals of any other 77 gender identity (e.g. nonbinary people). The HIV-IBM's needle-sharing network uses a contact network to 78 represent the action of sharing syringes among people who inject drugs (PWID), with a proportion of the 79 network assigned as HIV positive at the start of the simulation (see details below and in Appendix 1). The 80 network of needle sharing was created to represent needle sharing behaviour among PWID in the US.(20) 81 The HIV-IBM also simulates HIV testing and treatment in the synthetic population. Proportions of people 82 who get tested for HIV, PLWH who start treatment, and PLWH who adhere to treatment regimens were

83	based on data collected from published studies (Appendix 1, Table A5). The sexual network resulted from
84	individuals within the model interacting as they moved across the simulated city. Their movement was
85	simulated using a gravity model that has previously been used to model Ebola, COVID-19, and
86	mpox.(21–23)

87 The HIV-IBM aimed to assess the effects of reducing HIV stigma on HIV transmission. Thus, the HIV-

88 IBM simulates the impact of stigma at several points, as stigma can prevent people from getting tested,

89 delay the start of treatment, and reduce the probability of treatment adherence. We modelled three

90 different manifestations of stigma: anticipated stigma, internalised stigma, and experienced stigma (Table

91 1).(24)

92 Table 1: Types of stigma modelled

Stigma type	Affected behaviour	Source used in model
Anticipated stigma	Getting tested	(25)
	Adhering to ART	(26)
Internalised stigma	Starting ART	(27)
	Adhering to ART	(26)
Enacted Stigma	Adhering to ART	(26)

93

94 Studies investigating the effects of stigma typically use continuous scales to represent level of stigma 95 affecting the target population rather than dichotomous variables ("affected by stigma" or "not affected by 96 stigma").(28) Thus, the HIV-IBM included stigma using scale scores from different sources on the effects 97 of stigma on the HIV care continuum. Given the absence of a single standardized scale to quantify the 98 level of stigma types, we adopted scales reported in the studies from which we gathered information 99 about the associations of stigma with testing, starting treatment, and adhering to treatment (Appendix 1, 100 Table A3).

101 The parameters used to build the HIV-IBM starting population and its characteristics are reported in the

102 Appendix. The model simulation runs did not begin with a HIV-naïve population, but rather initiated with

103 a population representing the US population with current levels of HIV prevalence. We disaggregated the

104	number of cases in the starting population across sexual orientation, race, and ethnicity (Appendix 1,		
105	Table A5) (29–31). The starting populations in the HIV-IBM also included a fraction of non-tested		
106	individuals, PLWH who know their status but have not started HIV treatment, and PLWH who are not		
107	adherent to HIV treatment (Appendix 1, Table A5). The IBM-HIV simulated HIV transmission over a		
108	three-year time window. Weekly probabilities of HIV testing, initiating ART after a positive HIV test, and		
109	ART adherence were estimated at the individual level.		
110	The baseline model was calibrated to reflect HIV incidence reported for 2022, approximately 11.3		
111	infected every 100,000 people (32). Results are reported using the median and the 95% credible interval		
112	(CI, as 2.5 and 97.5 quantile) based on 10,000 simulations per scenario. We evaluate the effect of stigma		
113	on HIV transmission by simulating scenarios in which we changed the level (i.e., score) of each		
114	manifestation of stigma throughout the population. We compare the baseline model with two scenarios:		
115	• Anticipated, internalised, and experienced stigma reduced by 50%		
116	• Eliminating anticipated, internalised, and experienced stigma (i.e., simulated effects of 100%		
117	stigma reduction)		
118	We performed a sensitivity analysis to quantify the effect of anticipated, internalised, and experienced		
119	stigma on the HIV care continuum and HIV transmissions. A full description of the sensitivity analysis is		
120	provided in the Appendix.		
121	RESULTS		
122	The baseline model had an average annual HIV incidence of 12.6 (95% credible interval [CI]: 11.4-13.5		
123	new cases per 100,000 people, with 379 (95% CI: 242-405) incident HIV cases per year and 1,141 (95%		
124	CI: 931-1,350) incident HIV cases over the three-year time window (Figure 1, Figure 2, and Table 2). The		
125	modelled scenario reducing levels of anticipated, internalised, and experienced HIV stigma by 50%		
126	resulted in annual incidence of 9.6 (95% CI: 8.6-10.3) new cases per 100,000 people, an average of 288		

127 new cases per year (95% CI: 258-329), and an average of 872 (95% CI: 594-596) new cases at the end of

- 128 the three years (Figure 1, Figure 2, and Table 2). Eliminating anticipated, internalised, and experienced
- stigma resulted in an annual incidence of 6.8 (95% CI: 6.1-7.3) new cases per 100,000 people, an average
- 130 of 204 (95% CI:: 183-219) new cases per year, and an average of 612 (95% CI: 521-671) new cases at the
- 131 end of the three years equal to (Figure 1, Figure 2, and Table 2).

Baseline HIV stigma reduced Scenario **HIV stigma reduced** by 100% by 50% Estimate 95% CI* Estimate 95% CI Estimate 95% CI Mean annual incidence per 12.6 11.4 -13.5 9.6 8.6-10.3 6.8 6.1-7.3 100,000 people Mean new cases per 379 258-329 342-405 288 204 183-219 year Total number of new 1.141 931-1.350 872 594-956 612 521-671 cases Percentage of PLWH 86.7% 91.8% 96.1% 82.1-90.1% 87.2-94.1% 91.3-98.2% knowing their status Percentage of PLWH 80.8% 90.2% 81.1% who know their status 75.5-86.3% 73.2-85.3% 87.7-93.3% who are on treatment Percentage of PLWH 81.6% 90.2% 94.9% on treatment with 76.1-88.6% 87.7-93.3% 90.3-97.4% suppressed viral load

132 Table 2: Results of the three scenarios simulated with the HIV-IBM

133 *CI: credible interval

134 Stigma reduction had significant impacts throughout the HIV care continuum. Reducing stigma increased 135 the proportion of PLWH who know their status and the proportion of people on treatment who had 136 achieved viral load suppression (Table 2 and Figure 2). The fraction of PLWH who know their status 137 increased from 86.7% (95% CI: 82.1%-90.1%) to 91.8% (95% CI: 87.2%-94.1%) when stigma was 138 reduced by 50%, and to 96.1% (91.3%-98.2%) when stigma was eliminated. Eliminating stigma had a 139 slightly positive effect on HIV treatment initiation for PLWH with an HIV diagnosis: a 2.5% increase 140 (baseline: 80.8% [95% CI: 75.5%-86.3%] of PLWH with an HIV diagnosis who initiated treatment, and 141 100% reduction: 82.8% [95%: 78.5%-92.8%] who initiated treatment) (Table 2, and Figure 2). Viral 142 suppression among PLWH under treatment drastically increased comparing the baseline model and those 143 with reduced or eliminated stigma. Compared to viral suppression resulted obtained from the baseline

scenario (81.6% [95% CI: 76.1%-88.6%]), the HIV-IBM with 50% stigma reduction resulted in a 10.5% increase in viral suppression (90.2% [95% CI: 87.7%-93.3%]) among treated PLWH. Eliminating HIV stigma resulted in a 16.2% increase compared to baseline (94.9% [95% CI: 90.3%-97.4%]). The sensitivity analysis showed that reducing anticipated stigma affecting HIV testing provided the highest mean reduction of HIV incidence compared to other stigma effects (Figure 3). However, sensitivity analyses also showed that reducing experienced stigma affecting ART adherence had little effect on HIV incidence (Figure 3).

151 **DISCUSSION**

152 This paper introduces a framework for incorporating HIV stigma into mathematical models of the HIV 153 epidemic. Findings suggest that eliminating HIV stigma could have a large impact on HIV incidence and 154 make substantial progress towards the 95-95-95 UNAIDS targets, leading to achievement of the 1st 95% target and near-achievement of the 3rd target. Our results also suggest that interventions to reduce 155 156 anticipated stigma's effect on HIV testing could have the greatest single impact on HIV incidence of the 157 included stigma-reduction interventions. While our point estimates and their simulation bound intervals 158 are limited to the model and underlying synthetic population in a hypothetical U.S. city, the results show 159 an expected effect of stigma reduction that provides an initial estimate of the effects of potential 160 interventions. Application of this model's novel, dynamic approach in real-world settings, and to specific 161 subpopulations who experience higher levels of stigma, could strengthen the case for investment in 162 stigma reduction efforts; facilitate the exploration of specific, tailored stigma reduction strategies; and 163 offer insights to inform evidence-based policies and programming to reduce HIV stigma and curtail the 164 epidemic.

165 We are aware of three other mathematical models that have investigated the effects of stigma on the HIV

166 epidemic. Stover et al. incorporated internalised HIV stigma into a deterministic compartmental HIV

167 epidemic simulation model for each of 77 countries with a high burden of HIV.(19) Based on a

168 hypothetical scenario assuming that the 95-95-95 goals can be achieved only in the absence of

169 internalised stigma, they found that failure to reduce internalised stigma would substantially increase both HIV incidence and HIV-related mortality by inhibiting rates of HIV testing, treatment, and viral load 170 171 suppression. Because their model does not include anticipated or enacted stigma, it likely underestimates 172 the potential impact of stigma elimination. Prudden et al. used a probabilistic mathematical model to 173 estimate the impact of stigma on vertical transmission of HIV in South Africa.(18) Under the scenario of 174 universal access to ART for all pregnant women, the model predicted that eliminating stigma would avert 175 51% of all infant HIV acquisitions, with the largest impact on the treatment adherence stages of the 176 cascade.(18) Their model does not disaggregate various forms of stigma to guide intervention choices. 177 Further, by nature of its focus on pregnant women, the results are not easily translated to other 178 populations with different levels of engagement with the healthcare system and different motivations for 179 treatment.(33) Our model had results similar in magnitude to these two preceding models, but it expands 180 upon their work by separately modelling different forms of stigma at different stages of the prevention 181 and care cascade to allow more detailed and comprehensive estimates of the potential results of stigma 182 reduction efforts.

183 In contrast to Prudden et al. and Stover et al., Levy et al. estimated the effects of HIV-related stigma on 184 epidemic dynamics in Kenya by integrating a mechanistic model of HIV stigma—based on prevalence estimates of enacted and perceived stigma from the Demographic and Health Surveys and assumptions on 185 186 stigma dynamics—into a compartmental of HIV transmission dynamics.(17) Levy et al. found that 187 eliminating enacted stigma between 2004 and 2017 would have reduced HIV incidence from about 5% to 188 3%, while eliminating internalised stigma would have had little impact on incidence. Additionally, they 189 found that stigma elimination would have only a small impact on annual HIV incidence and HIV-related 190 mortality by 2030.(17) Key limitations to the model of Levy et al. are its reliance on fitted formulas rather 191 than epidemiologic data to estimate the prevalence of internalised stigma and the impact of stigma on 192 HIV outcomes, which may account for the differences in this model's findings compared to our own and 193 to those of Stover et al. and Prudden et al.(17-19)

The quantity and nature of the available data on HIV stigma posed significant challenges in 194 195 parameterizing the model. While data on the prevalence or severity of HIV stigma are plentiful, few 196 studies have tested the impact of stigma on HIV-related health outcomes, and those studies have shown 197 inconsistent results. A possible explanation for these inconsistencies is the lack of standard definitions and 198 measures for different forms of HIV stigma. We chose to model anticipated, enacted, and internalised 199 stigma which are among the most commonly studied forms of stigma, but other researchers have also 200 reported on *community* stigma, *public* stigma, *felt* stigma, *self* stigma, *structural* stigma, *professional* 201 stigma, and other forms. Further, the definitions and items used to measure these various forms of stigma 202 often overlap. For example, disclosure concerns have been classified as representing either internalised or 203 anticipated stigma, depending on the scale (34-36). When consensus exists on the forms and definitions 204 of stigma, multiple scales are still used to quantify stigma, which makes it difficult to compare research 205 results and use them to parametrize a model. There was also insufficient data to model interactions 206 between different types of stigma, such as the potential for internalized stigma to mediate effect of 207 experienced stigma on medication adherence.(37) Finally, studies use various techniques to model stigma 208 as an exposure, such as continues scores, z-scores, threshold levels, or percentiles for the study 209 population.. This variation makes results difficult to aggregate or compare across studies. These 210 challenges point to the need for greater consensus in stigma definitions, a more consistent approach to 211 analysing stigma across studies, and more well-designed studies to evaluate the impact of HIV-related 212 stigma on health outcomes, as well as dedicated resources and leadership to accomplish these objectives. 213 -For better and worse, the HIV-IBM model reflects the current state of HIV stigma measurement at 214 the level of the full population. The model's use of continuous scales for stigma instead of a dichotomous 215 "stigma" or "no stigma" model allows it to describe heterogenous experiences of stigma across the 216 population. It also provides insight into the effects of different manifestations of stigma on different

217 aspects of HIV prevention and treatment, which allows for a more nuanced understanding of how stigma

affects HIV transmission. The flexible nature of the model also makes it easy to adjust for future work

219 that provides further detail on specific populations, conditions, and interventions. The current model represents what the authors feel is a reasonable balance between fidelity (complex but true-to-life) and 220 221 tractability (simple but feasible to program), but as the availability of data improves, the HIV-IBM should 222 be also revisited and improved. The current iteration of the model does not capture intersectional stigma, 223 nor does it describe differences in stigma affecting people of different marginalized identities, e.g. by 224 race, ethnicity, gender, sexual orientation, etc. Importantly, while the current model includes people with 225 multiple patterns of sexual behaviour, it does not include people with gender identities other than "man" 226 or "woman". Future work building upon and expanding the HIV-IBM should consider these additional 227 variables as means for improving the fidelity and specificity of the model, and thereby increasing the 228 model's usefulness for understanding the effects of HIV stigma on the populations most affected by HIV. 229 Both UNAIDS and the U.S. National HIV/AIDS Strategy frame stigma as a societal barrier to achieving 230 the 95-95-95 targets, and have explicit goals to reduce stigma experienced by PLWH and people 231 disproportionately affected by HIV. (2,3) Our results suggest that eliminating or reducing stigma will, in 232 fact, help to attain the 95-95-95 targets. Multiple interventions have been shown to effectively reduce HIV 233 stigma among people living with HIV, healthcare workers, and the community (38–45), including 234 education, contact strategies, counselling, and structural changes to laws and policies.(39) While not 235 explicitly included in the current model, evidence suggests that stigma reduction may also improve other 236 health outcomes, such as depression, anxiety, social support, access to health and social services, and 237 overall quality of life.(46) Future iterations of this model could incorporate scenarios mimicking specific 238 evidence-based stigma reduction interventions at different levels of the health system and of society and 239 incorporate additional health outcomes to understand the broader impact of stigma reduction on the health 240 and well-being of PLWH. Although our model suggests that reducing anticipated stigma would have the 241 greatest impact on HIV testing and incidence, there are fewer evidence-based interventions to reduce this 242 form of stigma. Multiple studies show community members' negative attitudes towards people living with 243 HIV have declined over time, but this is not always accompanied by declines in anticipated stigma,

- 244 suggesting that to effectively reduce anticipated stigma, additional steps must be taken to convince
- individuals that others in the society have also changed their views.(47,48)

246 CONCLUSIONS

- 247 Our model framework provides a dynamic approach to understanding the role and estimating the effect of
- stigma in HIV transmission. Findings suggest that reducing HIV stigma could have a large impact on HIV
- 249 incidence and strengthen the case for investment in actions to reduce stigma and discrimination. This
- 250 model's novel approach could facilitate the exploration of stigma reduction strategies and offer insights to
- 251 inform evidence-based policies and interventions for reducing stigma and curtailing HIV.

252 **COMPETING INTERESTS**

253 The authors declare that they have no competing interests.

254 AUTHORS' CONTRIBUTIONS

- 255 DB, STR, GB, and LN conceptualized the research. KNM, RDS, and DB curated data inputs for the
- 256 model. DB developed the model and conducted the formal analysis. DB, STR, RDS, KNM, LN, JA, KKJ,
- 257 SMED, NB, and GB participated in model structuring and parameterization. LN and GB secured funding
- 258 for this project and provided supervision. STR, LN, and RDS provided project administration support.
- 259 DB, STR, and RDS wrote the first draft of the manuscript and GB, JA, LN, KNM, SMED, KS, NB, and
- 260 KKJ provided substantial revisions. All authors read and approved the final manuscript.

261 ACKNOWLEDGEMENTS

- 262 The authors thank members of the RTI Stigma Community of Practice for their contributions to the model
- 263 design and are grateful to the participants who contributed data to the many studies used to parameterize

the model.

265 FUNDING

266 This work was funded by the RTI Fellows' BUILD program at RTI International.

267 DATA AVAILABILITY STATEMENT

268 Data sharing not applicable – no new data generated

269 SUPPORTING INFORMATION

- 270 Appendix 1: Technical appendix.
- 271 Microsoft Word document. Contains details of parameter values and their sources as well as a more
- 272 detailed description of the modelling methods.

273 LIST OF ABBREVIATIONS

274 ART Antiretroviral therapy Credible interval 275 CI 276 HIV Human immunodeficiency virus Individual-based model representing the HIV epidemic 277 HIV-IBM 278 MSM Men who have sex with men 279 MSMSW Men who have sex with both men and women 280 MSW Men who have sex with women 281 WSM Women who have sex with men 282 WSW Women who have sex with women 283 WSWSM Women who have sex with both women and men 284 Pre-exposure prophylaxis PrEP People living with HIV 285 PLWH 286 People who inject drugs PWID 287 **REFERENCES**

- Centers for Disease Control and Prevention. HV Surveillance Supplemental Report: Estimated HIV Incidence and Prevalence in the United States, 2018–2022. 2024 May 21; Available from: https://stacks.cdc.gov/view/cdc/156513
- 290 https://stacks.cdc.gov/view/cdc/150515
- 291 2. UNAIDS. Global AIDS Strategy 2021-2026. End Inequalities. End AIDS. [Internet]. Geneva,
- Switzerland; 2021 [cited 2024 Sep 16]. Available from:
 https://www.unaids.org/en/resources/documents/2021/2021-2026-global-AIDS-strategy
- 294 3. The White House. National HIV/AIDS Strategy for the United States, 2022-2025. Washington, DC;
 2021.
- 4. Centers for Disease Control and Prevention. HV Surveillance Supplemental Report: Monitoring
 Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data United States
 and 6 Territories and Freely Associated States, 2022. 2024 May 21; Available from:
 https://stacks.cdc.gov/view/cdc/156511
- Turan B, Hatcher AM, Weiser SD, Johnson MO, Rice WS, Turan JM. Framing mechanisms linking
 HIV-related stigma, adherence to treatment, and health outcomes. Am J Public Health. 2017
 Jun;107(6):863–9.
- Rueda S, Mitra S, Chen S, Gogolishvili D, Globerman J, Chambers L, et al. Examining the
 associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a
 series of meta-analyses. BMJ Open. 2016 Jul 1;6(7):e011453.
- 306
 307
 308
 308
 309
 309
 309
 309
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3000
 3
- 8. Christopoulos KA, Neilands TB, Dilworth S, Lisha N, Sauceda J, Mugavero MJ, et al. Internalized HIV stigma predicts subsequent viremia in US HIV patients through depressive symptoms and antiretroviral therapy adherence. AIDS. 2020 Sep 1;34(11):1665–71.
- Gamarel KE, Nelson KM, Stephenson R, Santiago Rivera OJ, Chiaramonte D, Miller RL, et al.
 Anticipated HIV stigma and delays in regular HIV testing behaviors among sexually-active young gay,
 bisexual, and other men who have sex with men and transgender women. AIDS Behav. 2018
 Feb;22(2):522–30.
- Ssenyonjo J, Shrestha R, Copenhaver M. Influence of stigma on pre-exposure prophylaxis (PrEP)
 care continuum among men and transwomen who have sex with men (MTWSM) in the United States.
 Int J HIV AIDS Prev Educ Behav Sci. 2019 Dec;5(2):134–40.
- Lui CW, Dean J, Mutch A, Mao L, Debattista J, Lemoire J, et al. HIV testing in men who have
 sex with men: a follow-up review of the qualitative literature since 2010. AIDS Behav. 2018
 Feb;22(2):593-605.
- Babel RA, Wang P, Alessi EJ, Raymond HF, Wei C. Stigma, HIV risk, and access to HIV
 prevention and treatment services among men who have sex with men (MSM) in the United States: a
 scoping review. AIDS Behav. 2021 Nov;25(11):3574–604.
- Nawfal ES, Gray A, Sheehan DM, Ibañez GE, Trepka MJ. A systematic review of the impact of
 HIV-related stigma and serostatus disclosure on retention in care and antiretroviral therapy adherence

- among women with HIV in the United States/Canada. AIDS Patient Care STDS. 2024 Jan;38(1):23–
 49.
- Vermeer W, Gurkan C, Hjorth A, Benbow N, Mustanski BM, Kern D, et al. Agent-based model
 projections for reducing HIV infection among MSM: Prevention and care pathways to end the HIV
 epidemic in Chicago, Illinois. PLoS One. 2022;17(10):e0274288.
- Probert WJM, Sauter R, Pickles M, Cori A, Bell-Mandla NF, Bwalya J, et al. Projected outcomes
 of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the
 HPTN 071 [PopART] trial): a modelling study. Lancet HIV. 2022 Nov;9(11):e771–80.
- Abuelezam NN, McCormick AW, Surface ED, Fussell T, Freedberg KA, Lipsitch M, et al.
 Modelling the epidemiologic impact of achieving UNAIDS fast-track 90-90-90 and 95-95-95 targets in
 South Africa. Epidemiol Infect. 2019 Jan;147:e122.
- Levy B, Correia HE, Chirove F, Ronoh M, Abebe A, Kgosimore M, et al. Modeling the effect of
 HIV/AIDS stigma on HIV infection dynamics in Kenya. Bull Math Biol. 2021 Apr 5;83(5):55.
- Prudden HJ, Hamilton M, Foss AM, Adams ND, Stockton M, Black V, et al. Can mother-to-child
 transmission of HIV be eliminated without addressing the issue of stigma? Modeling the case for a
 setting in South Africa. PLOS ONE. 2017 Dec 8;12(12):e0189079.
- Stover J, Glaubius R, Teng Y, Kelly S, Brown T, Hallett TB, et al. Modeling the epidemiological
 impact of the UNAIDS 2025 targets to end AIDS as a public health threat by 2030. PLOS Medicine.
 2021 Oct 18;18(10):e1003831.
- Campbell EM, Jia H, Shankar A, Hanson D, Luo W, Masciotra S, et al. Detailed Transmission
 Network Analysis of a Large Opiate-Driven Outbreak of HIV Infection in the United States. J Infect
 Dis. 2017 Nov 27;216(9):1053–62.
- Bisanzio D, Reithinger R. Projected burden and duration of the 2022 Monkeypox outbreaks in non-endemic countries. The Lancet Microbe. 2022 Sep 1;3(9):e643.
- Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Gaudig M, et al. Targeted preventive
 vaccination campaigns to reduce Ebola outbreaks: An individual-based modeling study. Vaccine. 2023
 Jan 16;41(3):684–93.
- Bisanzio D, Reithinger R, Alqunaibet A, Almudarra S, Alsukait RF, Dong D, et al. Estimating the
 effect of non-pharmaceutical interventions to mitigate COVID-19 spread in Saudi Arabia. BMC
 Medicine. 2022 Feb 7;20(1):51.
- 357 24. Nyblade L, Mingkwan P, Stockton MA. Stigma reduction: an essential ingredient to ending AIDS
 358 by 2030. Lancet HIV. 2021 Feb 1;8(2):e106–13.
- 359 25. Golub SA, Gamarel KE. The impact of anticipated HIV stigma on delays in HIV testing
 360 behaviors: findings from a community-based sample of men who have sex with men and transgender
 361 women in New York City. AIDS Patient Care STDS. 2013 Nov;27(11):621–7.
- Earnshaw VA, Smith LR, Chaudoir SR, Amico KR, Copenhaver MM. HIV stigma mechanisms
 and well-being among PLWH: a test of the HIV stigma framework. AIDS Behav. 2013
 Jun;17(5):1785–95.

365 27. Pearson CA, Johnson MO, Neilands TB, Dilworth SE, Sauceda JA, Mugavero MJ, et al. Internalized HIV stigma predicts suboptimal retention in care among people living with HIV in the 366 367 United States. AIDS Patient Care STDS. 2021 May;35(5):188-93. 368 28. Earnshaw VA, Chaudoir SR. From conceptualizing to measuring HIV stigma: a review of HIV 369 stigma mechanism measures. AIDS Behav. 2009 Dec;13(6):1160-77. 370 Centers for Disease Control and Prevention. PrEP for HIV prevention in the U.S. [Internet]. 2023 29. 371 [cited 2024 Apr 30]. Available from: 372 https://web.archive.org/web/20240416105239/https://www.cdc.gov/nchhstp/newsroom/fact-373 sheets/hiv/PrEP-for-hiv-prevention-in-the-US-factsheet.html 30. 374 HIV.gov. U.S. statistics [Internet]. 2024 [cited 2024 Apr 30]. Available from: 375 https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics 376 AIDSVu. Understanding the current HIV epidemic in the United States [Internet]. [cited 2024 Apr 31. 377 30]. Available from: https://map.aidsvu.org/profiles/nation/usa/overview#/ 378 32. HIV.gov. U.S. statistics [Internet]. 2024 [cited 2024 Apr 30]. Available from: 379 https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics 380 33. Lytvyn L, Siemieniuk RA, Dilmitis S, Ion A, Chang Y, Bala MM, et al. Values and preferences of 381 women living with HIV who are pregnant, postpartum or considering pregnancy on choice of 382 antiretroviral therapy during pregnancy. BMJ Open. 2017 Dec 1;7(9):e019023. 383 34. Kalichman SC, Simbayi LC, Cloete A, Mthembu PP, Mkhonta RN, Ginindza T. Measuring AIDS 384 stigmas in people living with HIV/AIDS: the Internalized AIDS-Related Stigma Scale. AIDS Care. 385 2009 Jan;21(1):87–93. 386 Pantelic M, Boyes M, Cluver L, Thabeng M. "They say HIV is a punishment from God or from 35. 387 ancestors": cross-cultural adaptation and psychometric assessment of an HIV stigma scale for South 388 African adolescents living with HIV (ALHIV-SS). Child Indic Res. 2018;11(1):207–23. 389 Luseno WK, Field SH, Iritani BJ, Odongo FS, Kwaro D, Amek NO, et al. Pathways to 36. 390 Depression and Poor Quality of Life Among Adolescents in Western Kenya: Role of Anticipated HIV 391 Stigma, HIV Risk Perception, and Sexual Behaviors. AIDS and Behavior [Internet]. 2020; Available 392 from: https://doi.org/10.1007/s10461-020-02980-5 393 Kay ES, Rice WS, Crockett KB, Atkins GC, Batey DS, Turan B. Experienced HIV-Related 37. 394 Stigma in Health Care and Community Settings: Mediated Associations With Psychosocial and Health 395 Outcomes. Journal of acquired immune deficiency syndromes (1999). 2018;77(3):257-63. 396 38. Stangl AL, Lloyd JK, Brady LM, Holland CE, Baral S. A systematic review of interventions to 397 reduce HIV-related stigma and discrimination from 2002 to 2013: how far have we come? J Int AIDS 398 Soc. 2013 Nov 13;16(3Suppl 2):18734. 399 Nyblade L, Mingkwan P, Stockton MA. Stigma reduction: an essential ingredient to ending AIDS 39. 400 by 2030. Lancet HIV. 2021 Feb 1;8(2):e106–13. 401 40. Mak WWS, Mo PKH, Ma GYK, Lam MYY. Meta-analysis and systematic review of studies on 402 the effectiveness of HIV stigma reduction programs. Soc Sci Med. 2017 Sep;188:30–40.

403 404 405	41. syste HIV.	Pantelic M, Steinert JI, Park J, Mellors S, Murau F. "Management of a spoiled identity": matic review of interventions to address self-stigma among people living with and affected by BMJ Glob Health. 2019;4(2):e001285.
406 407	42. stign	Loutfy M, Tharao W, Logie C, Aden MA, Chambers LA, Wu W, et al. Systematic review of na reducing interventions for African/Black diasporic women. J Int AIDS Soc. 2015;18(1):19835.
408 409	43. in he	Feyissa GT, Lockwood C, Woldie M, Munn Z. Reducing HIV-related stigma and discrimination althcare settings: A systematic review of quantitative evidence. PLoS One. 2019;14(1):e0211298.
410 411	44. and r	Smith MK, Xu RH, Hunt SL, Wei C, Tucker JD, Tang W, et al. Combating HIV stigma in low- niddle-income healthcare settings: a scoping review. J Int AIDS Soc. 2020 Aug;23(8):e25553.
412 413	45. Stign	Aghaei A, Sakhaei A, Khalilimeybodi A, Qiao S, Li X. Impact of Mass Media on HIV/AIDS na Reduction: A Systematic Review and Meta-analysis. AIDS Behav. 2023 Oct;27(10):3414–29.
414 415 416	46. assoc serie	Rueda S, Mitra S, Chen S, Gogolishvili D, Globerman J, Chambers L, et al. Examining the ciations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a s of meta-analyses. BMJ open. 2016;6(7):e011453.
417 418 419	47. expa Imm	Chan BT, Tsai AC. HIV stigma trends in the general population during antiretroviral treatment nsion: analysis of 31 countries in sub-Saharan Africa, 2003–2013. JAIDS Journal of Acquired une Deficiency Syndromes. 2016 Aug 15;72(5):558.
420 421	48. sectio	J Visser M. Change in HIV-related stigma in South Africa between 2004 and 2016: a cross- onal community study. AIDS Care. 2018 Jun 3;30(6):734–8.
422		
423		
424		
425		
426		
427		
428		
429		
430		

- 431
- 432
- 433





Figure 2: Effect of stigma reduction on HIV testing, treatment, and viral load suppression: Comparison to UNAIDS 95-95-95 targets



Figure 3: Effects of 100% reduction in individual types of stigma

